{"id":"W3048067521","doi":"10.1080/10428194.2020.1795159","title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Ibrutinib; Bendamustine; Medicine; Chronic lymphocytic leukemia; Internal medicine; Rituximab; Ofatumumab; Placebo; Hazard ratio; Alemtuzumab; Oncology; Lymphoma; Gastroenterology; Leukemia; Confidence interval; Transplantation; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007902329,0.001132501,0.002168585,0.0004418424,0.000493983,0.001452067,0.0007873519,0.001026368,0.00303732],"category_scores_gemma":[0.003314793,0.0003644992,0.004153129,0.0007275958,0.0003228416,0.0008115117,0.0007784119,0.002151008,0.0007392192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001052333,"about_ca_system_score_gemma":0.001452672,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001791434,"about_ca_topic_score_gemma":0.005614587,"domain_scores_codex":[0.9981124,0.001017127,0.0001400718,0.0001562042,0.0003255622,0.0002486116],"domain_scores_gemma":[0.9973217,0.0007311414,0.0007540425,0.0002008157,0.0003943999,0.0005980574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7474092,0.006135631,0.07857556,0.002959307,0.02277497,0.0005122961,0.0003110316,0.004004108,0.01043721,0.0003701709,0.03078647,0.09572408],"study_design_scores_gemma":[0.3350535,0.1254936,0.4652851,0.0005257435,0.03140162,0.000661549,0.0002693234,0.001349997,0.004639004,0.0009018671,0.0342643,0.0001545045],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8991213,0.02930225,0.002425067,0.0027946,0.0006116029,0.003240521,0.04962428,0.0002054373,0.01267496],"genre_scores_gemma":[0.9015663,0.00523236,0.002436009,0.003375306,0.0005028456,0.002803805,0.07835006,0.00008668383,0.005646664],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007902329,"threshold_uncertainty_score":0.04179198,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02279744231098206,"score_gpt":0.2582515279847478,"score_spread":0.2354540856737657,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}